Alisertib is an orally administered small molecule inhibitor of Aurora A kinase. Aurora kinases are involved in cell division and inhibiting them may result in the inhibition of cell proliferation. In this Phase I study Alisertib is administered in patients with advanced solid tumors or relapsed lymphoma with varying degrees of hepatic function.
CBL0137 is a small molecule in the carbazole family affecting p53 and NF-kappa B signal transduction pathways. It is administered intravenously on days 1, 8 and 15 every 28 days in patients with metastatic or advanced solid tumors and refractory lymphomas.
MLN7243 is a small molecule inhibitor of ubiquitin-activating enzyme (UAE) with potential antineoplastic activity. MLN7243 is administered intravenously in patients with advanced solid tumors using 2 different schedules. Treatments will be on days 1, 4, 8 and 11 on a 21 day cycle or days 1, 8 and 15 on a 28 day cycle.
MLN9708 is an oral proteasome inhibitor. In this Phase I/Ib study it is administered in patients with relapsed/refractory multiple myeloma and advanced solid tumors who have normal renal function or severe renal impairment.
TVB-2640 is FASN (Fatty Acid Synthase) inhibitor. FASN is an enzyme important in tumor metabolism, lipid signaling and tumor cell survival. In this Phase I study it is administrated orally in patients with solid tumors.